<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01256879</url>
  </required_header>
  <id_info>
    <org_study_id>HP-00046139</org_study_id>
    <secondary_id>HHSF2232000910020C</secondary_id>
    <nct_id>NCT01256879</nct_id>
  </id_info>
  <brief_title>Cimetidine Biowaivers</brief_title>
  <official_title>Evaluation of Excipient Effects on Biopharmaceuticals Classification System (BCS) Class 3 Drug Cimetidine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland, Baltimore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Food and Drug Administration (FDA)</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Maryland, Baltimore</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to see if non-drug ingredients in capsules and oral solutions
      affect how well drugs are absorbed. This is called &quot;bioequivalence.&quot; Medications taken by
      mouth, such as capsules and solutions, need to be absorbed into the body in order to do any
      good. Capsules and solutions contain a drug, but also contain non-drug ingredients that are
      called excipients or fillers. Excipients in the capsules and solutions can impact how much
      drug is absorbed into the body. This is called &quot;bioINequivalence.&quot; Capsules and solutions in
      this research contain the drug cimetidine. This drug is being used since it has high water
      solubility (can dissolve in water) and low ability to be absorbed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators anticipate that common excipients do not cause bioINequivalence. 1) The
      hypothesize is that commonly used excipients in oral medications change the rate or extent of
      Class 3 drug absorption and result in bioINequivalence. 2) Alternative hypothesis is that
      commonly used excipients in oral medications do not change the rate or extent of Class 3 drug
      absorption and do not result in bioINequivalence.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC</measure>
    <time_frame>0-10 hours</time_frame>
    <description>pharmacokinetic exposure (ng*hr/ml)</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>CimTest-A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200mg cimetidine (as 2 capsules)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CimTest-B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200mg cimetidine (as 2 capsules)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sorbitol-free cimetidine solution</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>200mg cimetidine (as oral liquid)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Commercial cimetidine solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200mg cimetidine (as oral liquid)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drug: cimetidine</intervention_name>
    <description>cimetidine 200mg total dose (single dose) as either CimTest-A capsules, CimTest-B capsules, sorbitol-free solution, or commercial cimetidine solution</description>
    <arm_group_label>CimTest-A</arm_group_label>
    <arm_group_label>CimTest-B</arm_group_label>
    <arm_group_label>Commercial cimetidine solution</arm_group_label>
    <arm_group_label>Sorbitol-free cimetidine solution</arm_group_label>
    <other_name>Tagamet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or Female

          -  Age 18-55

          -  Healthy volunteers: Subjects in good health, as determined by screening evaluation
             that is not greater than 30 days before the first drug study visit

          -  Willing to avoid caffeine containing products 24 hours prior to and day of study
             visits

          -  Willing to stop all over the counter medications for 24 hours prior to and during
             study visits

          -  Able to provide informed consent

        Exclusion Criteria:

          -  Presence of significant medical disease (including cardiovascular, pulmonary,
             hematologic, endocrine, immunologic, neurologic, gastrointestinal or psychiatric)

          -  Presence of hepatic, renal disease

          -  Pregnant women, breast feeding or trying to become pregnant

          -  Excessive alcohol use (i.e. current physical, behavioral, or personal manifestations
             related to the abuse or dependency on alcohol)

          -  Routine use (i.e. daily or weekly) prescription medication except birth control pills

          -  Routine use (i.e. daily or weekly) use of acid blockers, antacids, anti-diarrhea,
             stimulants, appetite suppressants, or anti nausea medication or other drugs that
             modulate gastrointestinal function

          -  Currently taking cimetidine or medication known to interact with cimetidine

          -  Allergic to cimetidine

          -  Undergoing therapy for solid tumor or blood malignancy

          -  Any condition in which in the opinion of the PI or medical physician would increase
             risk to the subject or interfere with the integrity of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Polli, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland, Baltimore</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Rege BD, Yu LX, Hussain AS, Polli JE. Effect of common excipients on Caco-2 transport of low-permeability drugs. J Pharm Sci. 2001 Nov;90(11):1776-86.</citation>
    <PMID>11745735</PMID>
  </reference>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>November 15, 2010</study_first_submitted>
  <study_first_submitted_qc>December 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2010</study_first_posted>
  <results_first_submitted>March 17, 2015</results_first_submitted>
  <results_first_submitted_qc>August 13, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">August 28, 2019</results_first_posted>
  <last_update_submitted>August 13, 2019</last_update_submitted>
  <last_update_submitted_qc>August 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Maryland, Baltimore</investigator_affiliation>
    <investigator_full_name>James E Polli</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>cimetidine</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>formulation</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cimetidine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cimetidine</title>
          <description>cimetidine 200mg total dose (single dose)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25">25 started in this cross-over study but only 24 completed</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>CimTest-A</title>
              <participants_list>
                <participants group_id="P1" count="25">25 started this intervention but only 24 completed</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>CimTest-B</title>
              <participants_list>
                <participants group_id="P1" count="24">24 started this intervention and 24 completed</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Sorbitol-free Cimetidine Solution</title>
              <participants_list>
                <participants group_id="P1" count="24">24 started this intervention and 24 completed</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Commercial Cimetidine Solution</title>
              <participants_list>
                <participants group_id="P1" count="24">24 started this intervention and 24 completed</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>healthy subjects</population>
      <group_list>
        <group group_id="B1">
          <title>Cimetidine</title>
          <description>cimetidine 200mg total dose (single dose)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>AUC</title>
        <description>pharmacokinetic exposure (ng*hr/ml)</description>
        <time_frame>0-10 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental: CimTest-A</title>
            <description>cimetidine capsule with hydroxypropyl methylcellulose (HPMC), a type of filler
cimetidine: cimetidine 200mg total dose (single dose)</description>
          </group>
          <group group_id="O2">
            <title>Experimental: CimTest-B</title>
            <description>cimetidine capsule with magnesium stearate, a type of filler
cimetidine: cimetidine 200mg total dose (single dose)</description>
          </group>
          <group group_id="O3">
            <title>Active Comparator: Sorbitol-free Cimetidine Solution</title>
            <description>non-commercial cimetidine solution
cimetidine: cimetidine 200mg total dose (single dose)</description>
          </group>
          <group group_id="O4">
            <title>Experimental: Commercial Cimetidine Solution</title>
            <description>commercial cimetidine solution
cimetidine: cimetidine 200mg total dose (single dose)</description>
          </group>
        </group_list>
        <measure>
          <title>AUC</title>
          <description>pharmacokinetic exposure (ng*hr/ml)</description>
          <units>ng*hr/ml</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3896" spread="181"/>
                    <measurement group_id="O2" value="3661" spread="186"/>
                    <measurement group_id="O3" value="3495" spread="183"/>
                    <measurement group_id="O4" value="3512" spread="193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Each CimTest-A, CimTest-B, and Commercial Cimetidine Solution are compared to Active Comparator (i.e. Sorbitol-free Cimetidine Solution), as a percentage of Active Comparator, per routine FDA bioequivalence testing of AUC.</non_inferiority_desc>
            <other_analysis_desc>Bioequivalence testing of AUC, per FDA guidance, is applied. Each CimTest-A, CimTest-B, and Commercial Cimetidine Solution are compared to Active Comparator (i.e. Sorbitol-free Cimetidine Solution), as a percentage of Active Comparator, per routine FDA bioequivalence testing of AUC. The upper and lower 90% Confidence Interval for CimTest-A is 104.4% to 120.6%. The upper and lower 90% Confidence Interval for CimTest-B is 97.9% to 113.0%. The upper and lower 90% Confidence Interval for Commercial Cimetidine Solution is 93.2% to 107.7%.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>10 hours</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Experimental: CimTest-A</title>
          <description>cimetidine capsule with hydroxypropyl methylcellulose (HPMC), a type of filler
cimetidine: cimetidine 200mg total dose (single dose)</description>
        </group>
        <group group_id="E2">
          <title>Experimental: CimTest-B</title>
          <description>cimetidine capsule with magnesium stearate, a type of filler
cimetidine: cimetidine 200mg total dose (single dose)</description>
        </group>
        <group group_id="E3">
          <title>Active Comparator: Sorbitol-free Cimetidine Solution</title>
          <description>non-commercial cimetidine solution
cimetidine: cimetidine 200mg total dose (single dose)</description>
        </group>
        <group group_id="E4">
          <title>Experimental: Commercial Cimetidine Solution</title>
          <description>commercial cimetidine solution
cimetidine: cimetidine 200mg total dose (single dose)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>pain</sub_title>
                <description>pain at IV site</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>James Polli, Professor</name_or_title>
      <organization>U of Maryland</organization>
      <phone>410-706-8292</phone>
      <email>jpolli@rx.umaryland.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

